Company news

Knight Therapeutics, Inc. news in 2026

Knight Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Knight Therapeutics Reports Third Quarter 2026 Results

November 5, 2026

Notice of Knight Therapeutics' Third Quarter 2026 Results Conference Call

October 29, 2026

Knight Therapeutics Announces Regulatory Approval of NIKTIMVO® in Brazil

October 6, 2026

Knight Therapeutics Announces Launch of TAVALISSE® in Brazil

October 6, 2026

Kyowa Kirin and Knight Therapeutics Enter Into Exclusive Distribution Agreement for POTELIGEO® (mogamulizumab) for Cutaneous T-Cell Lymphoma (CTCL) Patients Across Latin America

September 29, 2026

Knight Therapeutics Enters into Exclusive Distribution Agreement with Kyowa Kirin International for Poteligeo® (Mogamulizumab)

September 29, 2026

Knight Therapeutics Inc. places No. 345 on The Globe and Mail’s eighth annual ranking of Canada's Top Growing Companies

September 25, 2026

Knight Therapeutics Announces Regulatory Submission of GEMTESA® in Canada

September 15, 2026

Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Colombia

September 1, 2026

Knight Therapeutics Announces Supplemental Regulatory Submission for MINJUVI® (tafasitamab) in Brazil

August 27, 2026

Knight Therapeutics Announces Launch of WYNZORA® in Canada

August 20, 2026

Knight Therapeutics Reports Second Quarter 2026 Results

August 6, 2026

Notice of Knight Therapeutics' Second Quarter 2026 Results Conference Call

July 30, 2026

Knight Therapeutics Announces Repayment of Revolving Credit Facility

June 17, 2026

Knight Announces Early Warning Filing Regarding Shares of Crescita

June 5, 2026

Knight to Present at the Jefferies 2026 Healthcare Conference in New York City

May 28, 2026

Knight Therapeutics Announces Launch of TAVALISSE® in Mexico

May 27, 2026

Knight to Present at the 2026 RBC Capital Markets Global Healthcare Conference in New York City

May 12, 2026

Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Brazil

May 8, 2026

Knight Therapeutics Reports First Quarter 2026 Results

May 7, 2026

Notice of Knight Therapeutics' First Quarter 2026 Results Conference Call

April 30, 2026

Knight to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference

April 15, 2026

Knight Therapeutics Inc. ranks on The Globe and Mail's second annual Canada's Top Growing Women-Led Companies and seventh annual Women Lead Here benchmark of executive gender diversity

March 27, 2026

Knight Amends Normal Course Issuer Bid

March 23, 2026

Knight Therapeutics Reports Fourth Quarter and Year-End 2025 Results

March 19, 2026

Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico

March 17, 2026

Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico

March 17, 2026

Knight Therapeutics Announces Approval of Additional Indication for MINJUVI® (tafasitamab) in Brazil

March 17, 2026

Knight Therapeutics Announces Approval of Additional Indication for MINJUVI® (tafasitamab) in Brazil

March 17, 2026

Notice of Knight Therapeutics' Fourth Quarter and Year End 2025 Results Conference Call

March 12, 2026

Knight Therapeutics Announces Regulatory Submission of NIKTIMVO® (Axatilimab) in Brazil

February 18, 2026

Knight Therapeutics Announces Regulatory Submission of NIKTIMVO® (Axatilimab) in Brazil

February 18, 2026

Calls in 2026

Decks in 2026